Effect of Endostar combined with Paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in NSCLC patients
Objective: To explore the effect of endostar combined with taxol on tumor markers, vascular endothelial growth factor, neuron-specific enolase, metalloproteinase and tumor cell proliferation and migration in NSCLC patients. Methods Patients with advanced NSCLC were studied. The patients in the co...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Editorial Board of Journal of Hainan Medical University
2019-10-01
|
Series: | Journal of Hainan Medical University |
Subjects: | |
Online Access: | http://www.hnykdxxb.com/PDF/201919/10.pdf |
id |
doaj-9f381fff4f6e43998491d7d31ff7ebb7 |
---|---|
record_format |
Article |
spelling |
doaj-9f381fff4f6e43998491d7d31ff7ebb72020-11-25T01:32:36ZengEditorial Board of Journal of Hainan Medical UniversityJournal of Hainan Medical University1007-12371007-12372019-10-0125194852Effect of Endostar combined with Paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in NSCLC patientsQi Yong-Jian1, 0Zeng Xue-Hua1,1 Lai Ju-Ju2, 2Zha Wang-Jian331. Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu, China1. Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, Jiangsu, China2. Department of Cardiology Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu, China3. Department of Respiratory & Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu, ChinaObjective: To explore the effect of endostar combined with taxol on tumor markers, vascular endothelial growth factor, neuron-specific enolase, metalloproteinase and tumor cell proliferation and migration in NSCLC patients. Methods Patients with advanced NSCLC were studied. The patients in the control group received chemotherapy with paclitaxel combined with cisplatin. Patients in the combination group received intravenous infusion of endostar on the basis of treatment of patients in the control group. 21 days was a cycle, and all patients were treated for 2 cycles. Fasting venous blood 3mL of all patients before and after treatment was collected, and CEA and saccharide antigen (CA50) were detected by radioimmunoassay. Vascular endothelial growth factor (VEGF), neuron-specific enolase (NSE), serum matrix metalloproteinase (MMP-2, MMP-9), high-mobility family protein athook 2 (HMGA 2) and high-mobility family protein B 1 (HMGB 1) were detected by ELISA. Results There were no significant differences in serum CA50, CEA, VEGF, NSE, mmp-2, mmp-9, HMGB 1, and HMGA 2 between the two groups before treatment (P>0.05). After two courses of chemotherapy, CA50, CEA, VEGF, NSE, MMP-2, MMP-9, HMGB 1, and HMGA 2 in the combination group and control group were significantly lower than before treatment (P<0.05), and the combination group was significantly lower than the control group (P<0.05). Conclusion Endostar combined with paclitaxel can enhance the chemotherapy effect of NSCLC patients, reduce the level of serum tumor markers, neuronal specific enolase and vascular endothelial growth factor, and inhibit the proliferation and migration of tumor cells.http://www.hnykdxxb.com/PDF/201919/10.pdfendostar; paclitaxel; nsclc; metalloproteinase; proliferation and migration |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qi Yong-Jian1, Zeng Xue-Hua1, Lai Ju-Ju2, Zha Wang-Jian3 |
spellingShingle |
Qi Yong-Jian1, Zeng Xue-Hua1, Lai Ju-Ju2, Zha Wang-Jian3 Effect of Endostar combined with Paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in NSCLC patients Journal of Hainan Medical University endostar; paclitaxel; nsclc; metalloproteinase; proliferation and migration |
author_facet |
Qi Yong-Jian1, Zeng Xue-Hua1, Lai Ju-Ju2, Zha Wang-Jian3 |
author_sort |
Qi Yong-Jian1, |
title |
Effect of Endostar combined with Paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in NSCLC patients |
title_short |
Effect of Endostar combined with Paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in NSCLC patients |
title_full |
Effect of Endostar combined with Paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in NSCLC patients |
title_fullStr |
Effect of Endostar combined with Paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in NSCLC patients |
title_full_unstemmed |
Effect of Endostar combined with Paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in NSCLC patients |
title_sort |
effect of endostar combined with paclitaxel on the proliferation and migration of metalloproteinases and tumor cells in nsclc patients |
publisher |
Editorial Board of Journal of Hainan Medical University |
series |
Journal of Hainan Medical University |
issn |
1007-1237 1007-1237 |
publishDate |
2019-10-01 |
description |
Objective: To explore the effect of endostar combined with taxol on tumor markers, vascular
endothelial growth factor, neuron-specific enolase, metalloproteinase and tumor cell
proliferation and migration in NSCLC patients. Methods Patients with advanced NSCLC
were studied. The patients in the control group received chemotherapy with paclitaxel
combined with cisplatin. Patients in the combination group received intravenous infusion
of endostar on the basis of treatment of patients in the control group. 21 days was a cycle,
and all patients were treated for 2 cycles. Fasting venous blood 3mL of all patients before
and after treatment was collected, and CEA and saccharide antigen (CA50) were detected
by radioimmunoassay. Vascular endothelial growth factor (VEGF), neuron-specific enolase
(NSE), serum matrix metalloproteinase (MMP-2, MMP-9), high-mobility family protein athook
2 (HMGA 2) and high-mobility family protein B 1 (HMGB 1) were detected by ELISA.
Results There were no significant differences in serum CA50, CEA, VEGF, NSE, mmp-2,
mmp-9, HMGB 1, and HMGA 2 between the two groups before treatment (P>0.05). After
two courses of chemotherapy, CA50, CEA, VEGF, NSE, MMP-2, MMP-9, HMGB 1, and
HMGA 2 in the combination group and control group were significantly lower than before
treatment (P<0.05), and the combination group was significantly lower than the control group
(P<0.05). Conclusion Endostar combined with paclitaxel can enhance the chemotherapy effect
of NSCLC patients, reduce the level of serum tumor markers, neuronal specific enolase and
vascular endothelial growth factor, and inhibit the proliferation and migration of tumor cells. |
topic |
endostar; paclitaxel; nsclc; metalloproteinase; proliferation and migration |
url |
http://www.hnykdxxb.com/PDF/201919/10.pdf |
work_keys_str_mv |
AT qiyongjian1 effectofendostarcombinedwithpaclitaxelontheproliferationandmigrationofmetalloproteinasesandtumorcellsinnsclcpatients AT zengxuehua1 effectofendostarcombinedwithpaclitaxelontheproliferationandmigrationofmetalloproteinasesandtumorcellsinnsclcpatients AT laijuju2 effectofendostarcombinedwithpaclitaxelontheproliferationandmigrationofmetalloproteinasesandtumorcellsinnsclcpatients AT zhawangjian3 effectofendostarcombinedwithpaclitaxelontheproliferationandmigrationofmetalloproteinasesandtumorcellsinnsclcpatients |
_version_ |
1725081039479504896 |